Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 106.85%.

  • Ultragenyx Pharmaceutical's EBIT Margin fell 122300.0% to 106.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.27%, marking a year-over-year increase of 162200.0%. This contributed to the annual value of 95.67% for FY2024, which is 354100.0% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's EBIT Margin stood at 106.85%, which was down 122300.0% from 64.8% recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's EBIT Margin ranged from a high of 64.8% in Q2 2025 and a low of 248.14% during Q3 2022
  • Over the past 5 years, Ultragenyx Pharmaceutical's median EBIT Margin value was 110.02% (recorded in 2021), while the average stood at 124.3%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 2251100bps in 2021, then crashed by -1381200bps in 2022.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's EBIT Margin stood at 122.99% in 2021, then dropped by -15bps to 140.91% in 2022, then surged by 32bps to 95.81% in 2023, then rose by 23bps to 74.16% in 2024, then tumbled by -44bps to 106.85% in 2025.
  • Its last three reported values are 106.85% in Q3 2025, 64.8% for Q2 2025, and 102.62% during Q1 2025.